WO2002062299A3 - Improved controlled release oral dosage form - Google Patents

Improved controlled release oral dosage form Download PDF

Info

Publication number
WO2002062299A3
WO2002062299A3 PCT/US2002/003523 US0203523W WO02062299A3 WO 2002062299 A3 WO2002062299 A3 WO 2002062299A3 US 0203523 W US0203523 W US 0203523W WO 02062299 A3 WO02062299 A3 WO 02062299A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
controlled release
oral dosage
release oral
improved controlled
Prior art date
Application number
PCT/US2002/003523
Other languages
French (fr)
Other versions
WO2002062299A2 (en
Inventor
Boyong Li
Chih-Ming Chen
Xiu Xiu Cheng
Avinash Nangia
Original Assignee
Andrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc
Priority to JP2002562307A priority Critical patent/JP2005510449A/en
Priority to CA2433915A priority patent/CA2433915C/en
Priority to EP02723104A priority patent/EP1357898A4/en
Publication of WO2002062299A2 publication Critical patent/WO2002062299A2/en
Publication of WO2002062299A3 publication Critical patent/WO2002062299A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)

Abstract

A once a day bupropion hydrochloride formulation comprising applying a bupropion/cellulose ether suspension to inert spheres wherein the spheres are further divided and coated with two types of film being, an enteric coating and a hydrophobic coating, wherein the active drug is then released at various pH throughout the gastrointestinal tract maintaining a therapeutic range over an extended period of time.
PCT/US2002/003523 2001-02-08 2002-02-08 Improved controlled release oral dosage form WO2002062299A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002562307A JP2005510449A (en) 2001-02-08 2002-02-08 Improved controlled release oral dosage form
CA2433915A CA2433915C (en) 2001-02-08 2002-02-08 Improved controlled release oral dosage form
EP02723104A EP1357898A4 (en) 2001-02-08 2002-02-08 Improved controlled release oral dosage form

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26745601P 2001-02-08 2001-02-08
US26745701P 2001-02-08 2001-02-08
US60/267,456 2001-02-08
US60/267,457 2001-02-08

Publications (2)

Publication Number Publication Date
WO2002062299A2 WO2002062299A2 (en) 2002-08-15
WO2002062299A3 true WO2002062299A3 (en) 2003-04-24

Family

ID=26952450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003523 WO2002062299A2 (en) 2001-02-08 2002-02-08 Improved controlled release oral dosage form

Country Status (3)

Country Link
EP (1) EP1357898A4 (en)
CA (3) CA2685214C (en)
WO (1) WO2002062299A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
CA2601800C (en) * 2005-03-14 2013-12-03 Nitin Bhalachandra Dharmadhikari Oral drug delivery system
US8394415B2 (en) 2006-11-21 2013-03-12 Mcneil-Ppc, Inc Modified release analgesic suspensions
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US8956654B2 (en) 2009-06-02 2015-02-17 Dow Global Technologies Llc Sustained release dosage form
CN110200947A (en) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 A kind of Bupropion enteric sustained-release pellet capsule and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427798A (en) * 1992-08-14 1995-06-27 Burroughs Wellcome Co. Controlled sustained release tablets containing bupropion
US5800836A (en) * 1992-08-05 1998-09-01 F. H. Faulding & Co. Limited Pelletized pharmaceutical composition
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800836A (en) * 1992-08-05 1998-09-01 F. H. Faulding & Co. Limited Pelletized pharmaceutical composition
US5427798A (en) * 1992-08-14 1995-06-27 Burroughs Wellcome Co. Controlled sustained release tablets containing bupropion
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1357898A4 *

Also Published As

Publication number Publication date
EP1357898A4 (en) 2005-07-13
CA2685214A1 (en) 2002-08-15
CA2685214C (en) 2013-01-22
CA2433915A1 (en) 2002-08-15
CA2433915C (en) 2010-04-20
CA2796884A1 (en) 2002-08-15
EP1357898A2 (en) 2003-11-05
WO2002062299A2 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
JP3877329B2 (en) Multiparticulate pulsatile dosing system
ATE380022T1 (en) MULTIPARTICULAR MEDICINAL FORM CONTAINING AT LEAST TWO DIFFERENTLY COATED PELLET FORMS
CA2121870A1 (en) Controlled release drug delivery device
CA2290531A1 (en) Pharmaceutical formulation of omeprazole
ATE391496T1 (en) FLAVOR-MASKED PHARMACEUTICAL FORMULATIONS
IL142474A0 (en) Pharmaceutical formulation comprising omeprazole
WO2002072034A3 (en) Chronotherapeutic dosage forms
CA2181502A1 (en) Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
CA2315261A1 (en) Oral pharmaceutical extended release dosage form
CA2377916A1 (en) Taste masked pharmaceutical liquid formulations
ATE450259T1 (en) ORAL DOSAGE FORM CONTAINING A THERAPEUTIC ACTIVE INGREDIENT AND AN COUNTERACTIVE ACTIVE INGREDIENT
CA2046739A1 (en) Coated solid medicament form having releasability in large intestine
CA2277017A1 (en) Rapidly releasing and taste-masking pharmaceutical dosage form
CY1107576T1 (en) EXTREMELY RELEASE OF WATER SOLUBLE MEDICINAL SUBSTANCES
WO2002028376A3 (en) Chrono delivery formulations and method of use thereof
WO2001013898A3 (en) Pharmaceutical formulations with different release times
WO2002062299A3 (en) Improved controlled release oral dosage form
WO2001022944A8 (en) Oral controlled release formulations
WO2007054565A3 (en) New stabilized galenic formulations comprising lansoprazole and their preparation
WO2010122574A3 (en) Coated capsule
WO2002019993A8 (en) Granular preparations for oral administration
ATE535235T1 (en) CONTROLLED RELEASE MEDICINAL CONTAINING GALANTHAMINE
TH51175A (en) A controlled-release formulation for oral use.
TH34252A (en) An extended-release sisapride mini-tablet formulation.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002253907

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2433915

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002723104

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002562307

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002723104

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002723104

Country of ref document: EP